|
KMID : 0670719990040020055
|
|
Journal of the Korean Society Hyperthermia Oncology
1999 Volume.4 No. 2 p.55 ~ p.70
|
|
|
Hyperthermia of Malignant Brain Tumors: The Niigata Experiences
|
|
Ryuichi Tanaka
|
|
|
Abstract
|
|
|
During past 15 year, we have studied on radiofrequency(RF) capacitive and interstitial
hyperthermia for malignant brain tumors in collaboration with engineering groups. In
this presentation, I describe our clinical experiences of RF interstitial hyperthermia for
malignant brain tumors. We have developed RF interstitial heating system using 13.56
MHz RF needle antennas. A single or double stainless steel needle antennas with a
diameter of 1.3 ㎜ were inserted into the tumor (CE lesion on CT) using CT-guided
stereotaxic techniquc. The RF output was controlled to heat the margin of the CE lesion
of the tumor up to 42.5℃ in the eloquent area and 43.0℃ in the non-eloquent area for
60 minutes. The temperatures along two lines penetrating the tumor in two dimensions
were continuously monitored during heating. Heating was repeated 3-4 times combined
with (29 primary cases) or without conventional radiation (25 recurrent cases). Heating
was done without anesthesia and the patients complained no pain or heat sensation
during heating. The treated tumors showed CR in 11, PR in 17, ST in 26 and PD in 1
cases, respectively. Extensive necrosis was observed in many cases evaluated as ST.
Minor complications such as transient symptomatic brain edema in 5, liquorrhea in 2 and
subcutaneous infection in 1 cases were occurred. In conclusion, RF interstitial
hyperthermia can be a new powerful modality in multidisplinary treatment of malignant
gliomas including deep-seated tumors. To combine with this interstitial hyperthermia, we
have developed a new drug delivery system using thermosensitive liposomes. We made
liposomes containing CDDP or Adriamycin which can be released selectively in the
heated area when heated over 40℃ after intravascular administration. Our experimental
studies demonstrated promising results in delivering the drugs to brain tumor and
providing greater antitumor effect.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|